These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 11716800)

  • 1. Vasopeptidase inhibition and endothelial function in hypertension.
    d'Uscio LV; Lüscher TF
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency].
    Kolloch R; Offers E
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860
    [No Abstract]   [Full Text] [Related]  

  • 5. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
    Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopeptidase inhibition: a double-edged sword?
    Campbell DJ
    Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
    Battistini B; Daull P; Jeng AY
    Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
    Kubota E; Dean RG; Hubner RA; Balding LC; Johnston CI; Burrell LM
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S31-3. PubMed ID: 11716804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
    Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
    Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
    Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibition for blood pressure control: emerging experience.
    Quaschning T
    Curr Pharm Des; 2005; 11(25):3293-9. PubMed ID: 16250856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.